Is a Shorter Trastuzumab Duration a CostEffective Option in HER2 Breast Cancer

Is a Shorter Trastuzumab Duration a Cost-Effective Option in HER2+ Breast Cancer?

10:02 EDT 1 Nov 2018 | Cancer Networks

Researchers compared the cost effectiveness of two durations of trastuzumab in HER2+ breast cancer patients.

More From BioPortfolio on "Is a Shorter Trastuzumab Duration a Cost-Effective Option in HER2+ Breast Cancer?"